OVERCOMING THE INNATE RESISTANCE OF CANCER TO THERAPY
Trento, Italy | June 25-26, 2018
Head of Scientific Committee:David M. Livingston
Chairpersons: Alberto Bardelli, Massimo Loda, Pier Paolo Pandolfi, Stefano Piccolo
Focus and Goals: Currently, oncologists and cancer scientists face an abiding problem of major proportion, namely the emergence of resistance of certain cancers-some very common- to any therapy during their course. For some of these tumors, such as melanoma and kidney cancer, immune therapy has shown remarkable effects, but only a small fraction of patients undergo extended therapeutic responses. For prostate cancer patients whose tumors develop anti-androgen therapy resistance, further therapy has largely failed. And for cancers like Glioblastoma, pancreatic cancer, mesothelioma, and chemotherapy and marrow transplant-resistant acute myelogenous leukemia, a pathway to therapeutic success is not yet apparent. The thrust of this meeting will be to explore the molecular and biological sources of historical therapeutic resistance in these cancers and to assess the most promising opportunities for overcoming it.
Further details are also available http://www.pezcoller.it/en/symposium.html
| Download flyer |